Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics (Nasdaq: KPTI) reported Q2 2025 financial results with total revenue of $37.9 million, including U.S. XPOVIO net product revenue of $29.7 million, up 6% year-over-year. The company reaffirmed its full-year 2025 total revenue guidance of $140-155 million while updating U.S. XPOVIO revenue guidance to $110-120 million.
Key developments include the imminent completion of patient screening for the Phase 3 SENTRY trial in myelofibrosis, with top-line results expected in March 2026. However, the company faces financial challenges with $52.0 million in cash as of June 30, 2025, down from $109.1 million at year-end 2024. Karyopharm is actively exploring financing transactions and strategic alternatives to extend its cash runway beyond the October 2025 maturity of its convertible notes.
Karyopharm Therapeutics (Nasdaq: KPTI) ha comunicato i risultati finanziari del secondo trimestre 2025 con ricavi totali di 37,9 milioni di dollari, di cui 29,7 milioni di dollari di ricavi netti negli Stati Uniti da XPOVIO, in aumento del 6% su base annua. L'azienda ha confermato la guidance sui ricavi totali per l'intero 2025 di 140-155 milioni di dollari aggiornando contestualmente la guidance per i ricavi statunitensi di XPOVIO a 110-120 milioni di dollari.
Tra gli sviluppi principali figura il prossimo completamento dello screening dei pazienti per lo studio di fase 3 SENTRY nella mielofibrosi, con risultati principali attesi per marzo 2026. Tuttavia, la società affronta difficoltà finanziarie con 52,0 milioni di dollari in cassa al 30 giugno 2025, in calo rispetto ai 109,1 milioni di fine 2024. Karyopharm sta attivamente valutando operazioni di finanziamento e alternative strategiche per estendere la propria liquidità oltre la scadenza di ottobre 2025 delle obbligazioni convertibili.
Karyopharm Therapeutics (Nasdaq: KPTI) informó resultados financieros del segundo trimestre de 2025 con ingresos totales de $37.9 millones, incluidos $29.7 millones de ingresos netos por XPOVIO en EE. UU., un aumento del 6% interanual. La compañía reafirmó su guía de ingresos totales para todo 2025 de $140-155 millones y actualizó la guía de ingresos de XPOVIO en EE. UU. a $110-120 millones.
Entre los hitos clave se encuentra la inminente finalización del cribado de pacientes del ensayo de fase 3 SENTRY en mielofibrosis, con resultados principales esperados en marzo de 2026. No obstante, la empresa afronta retos financieros con $52.0 millones en caja al 30 de junio de 2025, frente a $109.1 millones a finales de 2024. Karyopharm está explorando activamente operaciones de financiación y alternativas estratégicas para prolongar su liquidez más allá del vencimiento en octubre de 2025 de sus notas convertibles.
Karyopharm Therapeutics (Nasdaq: KPTI)는 2025년 2분기 재무실적을 발표했으며, 총수익 37.9백만 달러 중 미국 XPOVIO 순매출 29.7백만 달러로 전년 동기 대비 6% 증가했습니다. 회사는 2025년 전체 총수익 가이던스 $140-155 million을 재확인하면서 미국 XPOVIO 매출 가이던스를 $110-120 million으로 업데이트했습니다.
주요 사항으로는 골수섬유증 대상 3상 SENTRY 임상의 환자 선별이 곧 완료될 예정이며, 주요 결과는 2026년 3월 발표될 것으로 예상됩니다. 다만 회사는 2025년 6월 30일 기준 현금 52.0백만 달러로 재무적 어려움을 겪고 있는데, 이는 2024년 말의 109.1백만 달러에서 감소한 수치입니다. Karyopharm은 2025년 10월 전환사채 만기 이후 현금 유동성을 연장하기 위해 자금 조달 거래 및 전략적 대안을 적극적으로 모색하고 있습니다.
Karyopharm Therapeutics (Nasdaq: KPTI) a publié ses résultats financiers du deuxième trimestre 2025 avec un chiffre d'affaires total de 37,9 millions de dollars, dont 29,7 millions de dollars de ventes nettes de XPOVIO aux États-Unis, en hausse de 6 % en glissement annuel. La société a réaffirmé sa prévision de chiffre d'affaires total pour 2025 de 140–155 millions de dollars tout en actualisant ses prévisions de ventes de XPOVIO aux États-Unis à 110–120 millions de dollars.
Parmi les faits marquants figure l'achèvement imminent du criblage des patients pour l'essai de phase 3 SENTRY en myélofibrose, les résultats principaux étant attendus en mars 2026. Toutefois, la société fait face à des difficultés financières avec 52,0 millions de dollars en trésorerie au 30 juin 2025, contre 109,1 millions de dollars à la fin de 2024. Karyopharm explore activement des opérations de financement et des alternatives stratégiques pour prolonger sa piste de trésorerie au-delà de l'échéance d'octobre 2025 de ses obligations convertibles.
Karyopharm Therapeutics (Nasdaq: KPTI) meldete die Finanzergebnisse für das zweite Quartal 2025 mit Gesamtumsatz von 37,9 Mio. USD, darunter 29,7 Mio. USD Nettoumsatz in den USA durch XPOVIO, ein Anstieg von 6% gegenüber dem Vorjahr. Das Unternehmen bestätigte seine Jahresumsatzprognose für 2025 von 140–155 Mio. USD und passte die Prognose für den US-Umsatz von XPOVIO auf 110–120 Mio. USD an.
Wesentliche Entwicklungen sind das bevorstehende Ende des Patientenscreenings für die Phase-3-Studie SENTRY bei Myelofibrose; die Top-Line-Ergebnisse werden für März 2026 erwartet. Gleichzeitig sieht sich das Unternehmen mit finanziellen Herausforderungen konfrontiert: 52,0 Mio. USD an liquiden Mitteln zum 30. Juni 2025, gegenüber 109,1 Mio. USD zum Ende 2024. Karyopharm prüft aktiv Finanzierungsoptionen und strategische Alternativen, um die Liquidität über die Fälligkeit der Wandelanleihen im Oktober 2025 hinaus zu verlängern.
- U.S. XPOVIO revenue increased 6% year-over-year to $29.7 million
- Royalty revenue grew 28% to $1.6 million compared to Q2 2024
- Phase 3 SENTRY trial nearing full enrollment with 350 patients
- R&D and SG&A expenses decreased due to cost reduction initiatives
- Net loss of $37.3 million in Q2 2025 compared to net income of $23.8 million in Q2 2024
- Cash position declined significantly to $52.0 million from $109.1 million at year-end 2024
- Company faces liquidity concerns with convertible notes due October 2025
- Total revenue decreased to $37.9 million from $42.8 million in Q2 2024
Insights
Karyopharm faces cash runway concerns despite modest XPOVIO growth; approaching critical clinical milestones amid urgent financing needs.
Karyopharm's Q2 results reveal a concerning financial position despite modest commercial progress. While U.S. XPOVIO revenue increased
The liquidity crisis is evident in management's explicit statement that current funds will only support operations until the
On the clinical front, the nearing completion of enrollment in the Phase 3 SENTRY myelofibrosis trial represents a critical milestone, with topline results expected in March 2026. However, this timeline creates a problematic gap between the October 2025 debt maturity and potential clinical catalysts that could drive value.
The updated revenue guidance shows reduced confidence in XPOVIO's commercial performance, with U.S. product revenue guidance lowered to
The company's negative cash flow remains substantial, with quarterly net loss of
While the myelofibrosis program shows promise, particularly in addressing patients with thrombocytopenia, investors should recognize that Karyopharm faces an existential financing challenge that will likely result in significant dilution or strategic transactions before clinical readouts can potentially drive value.
– New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 –
– Total Revenue was
– Reaffirms Full-Year 2025 Total Revenue Guidance of
– The Company is Exploring Financing Transactions and Strategic Alternatives to Extend its Cash Runway and Maximize Value –
– Conference Call Scheduled for Today at 8:00 a.m. ET –
"As we continue to seek potential financing and strategic alternatives to extend our cash runway and enhance liquidity, I am excited to announce that we are in our final weeks of enrolling our Phase 3 SENTRY trial and are on track to report top-line data from this pivotal trial in March 2026," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "Over the past seven years, we have led the development of a growing body of evidence supporting the role of XPO1 inhibition in myelofibrosis and are optimistic about selinexor's potential in this disease. Completing enrollment is a very important step in our journey to potentially redefine the standard-of-care in myelofibrosis and provide a transformational opportunity for patients and our organization, pending positive data."
Second Quarter 2025 Highlights
XPOVIO Commercial Performance
U.S. net product revenue was$29.7 million $28.0 million - Demand for XPOVIO was consistent in the second quarter of 2025 compared to the second quarter of 2024, with the community setting continuing to drive approximately
60% of overall net product revenue. - Expanded global patient access for selinexor is translating into growth in royalty revenue from Menarini, Antengene and other international partners. Royalty revenue increased
28% to$1.6 million
Research and Development (R&D) Highlights
Myelofibrosis
- The Phase 3 SENTRY trial (XPORT-MF-034; NCT04562389) is nearing full enrollment and the Company expects new patient screening will be closed this week. SENTRY is targeting 350 patients for enrollment and is evaluating 60 mg once-weekly selinexor in combination with ruxolitinib compared to ruxolitinib plus placebo. The preliminary baseline characteristics for patients enrolled in SENTRY are representative of the intended patient population. In addition, preliminary blinded aggregate safety data from the first 61 patients with a median follow-up of greater than 12 months may suggest improvements in both hematologic and non-hematologic treatment emergent adverse events as compared to the Phase 1 data evaluating selinexor 60 mg weekly in combination with standard of care ruxolitinib in JAKi-naïve myelofibrosis patients, as well as historical ruxolitinib monotherapy data. The Company cautions that the preliminary baseline characteristics and preliminary blinded aggregate safety data may not be reflective of the actual top-line data.
- Presented data from the XPORT-MF-035 (NCT04562870) Phase 2, randomized, open-label trial of selinexor versus physician's-choice in hard-to-treat patients with heavily pretreated myelofibrosis (N=24) at the European Hematology Association (EHA) 2025 Congress. The data suggest the potential for single-agent clinical activity with selinexor, including spleen volume reduction, symptom improvement, hemoglobin stabilization, and evidence of disease modification. A copy of the poster that was presented at EHA, titled "A Study to Evaluate Single-Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis" is available under "Publications and Presentations" in the Investor section of the Company's website.
- The Company continues to enroll JAKi-naïve myelofibrosis patients with moderate thrombocytopenia (defined as having platelet counts between 50,000 and 100,000) in the selinexor 60 mg cohort of the Phase 2 SENTRY-2 trial (XPORT-MF-044; NCT05980806). The Company plans to amend the protocol for SENTRY-2 to also include patients with platelet counts above 100,000, which will expand the number of patients that are eligible to participate in the trial. Approximately
10% to15% of patients with myelofibrosis have platelet counts between 50,000 and 100,0001. The Company expects to report top-line data from all patients in the 60 mg cohort with at least 24 weeks of follow-up in 2026.
1 Tremblay et al. Thrombocytopenia in Patients With Myelofibrosis: A Practical Management Guide, Clinical Lymphoma Myeloma and Leukemia Vol 22 Dec 2022 |
Endometrial Cancer
- Enrollment continues in the Phase 3 XPORT-EC-042 (NCT05611931) trial evaluating selinexor as a maintenance-only therapy following systemic therapy versus placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer.
Multiple Myeloma
- Enrollment of approximately 120 patients in the Phase 3 XPORT-MM-031 trial (EMN29; NCT05028348) was completed in the fourth quarter of 2024. The trial is being conducted in collaboration with the European Myeloma Network and is evaluating the all-oral combination of selinexor 40 mg, pomalidomide and dexamethasone (SPd40) in patients with previously treated multiple myeloma who received an anti-CD38 in their immediate prior line of therapy.
Anticipated Catalysts and Operational Objectives
Myelofibrosis
- The Company expects new patient screening will be closed for the Phase 3 SENTRY trial this week with top-line data expected in March 2026.
Multiple Myeloma
- Maintain the Company's commercial foundation in the increasingly competitive multiple myeloma marketplace and drive increased XPOVIO revenues.
- Continue to support global launches by our partners following regulatory and reimbursement approvals for selinexor in ex-
U.S. territories. - Continue to follow patients that are enrolled in the Phase 3 XPORT-MM-031 (EMN29) trial. The Company expects to report top-line data from this event-driven trial in the first half of 2026.
Endometrial Cancer
- Continue to enroll patients into the Phase 3 XPORT-EC-042 trial of selinexor as a maintenance monotherapy for patients with TP53 wild-type advanced or recurrent endometrial cancer. The Company expects to report top-line data from this event-driven trial in mid-2026.
2025 Financial Outlook
Based on its current operating plans, Karyopharm expects the following for full year 2025:
- Total revenue to be in the range of
$140 million $155 million U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners. U.S. XPOVIO net product revenue to be in the range of$110 million $120 million - R&D and selling, general and administrative (SG&A) expenses to be in the range of
$240 million $250 million - The Company expects its existing liquidity, including the revenue it expects to generate from XPOVIO net product sales and its license agreements, will be sufficient to fund its planned operations to the maturity of its senior convertible notes due October 2025 (Remaining 2025 Notes). Excluding the
$24.5 million $25.0 million
Second Quarter 2025 Financial Results
Total revenue: Total revenue for the second quarter of 2025 was
Net product revenue: Net product revenue for the second quarter of 2025 was
License and other revenue: License and other revenue for the second quarter of 2025 was
Cost of sales: Cost of sales for the second quarter of 2025 was
R&D expenses: R&D expenses for the second quarter of 2025 were
SG&A expenses: SG&A expenses for the second quarter of 2025 were
Interest income: Interest income for the second quarter of 2025 was
Interest expense: Interest expense for the second quarter of 2025 was
Gain on Extinguishment of Debt and Other (expense) income: Other expense for the second quarter of 2025 was
Net (loss) income: Karyopharm reported a net loss of
Cash position: Cash, cash equivalents, restricted cash and investments as of June 30, 2025 totaled
Conference Call Information
Karyopharm will host a conference call today, August 11, 2025, at 8:00 a.m. Eastern Time, to discuss the second quarter 2025 financial results, the financial outlook for 2025 and to provide other business updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website. An archived webcast will be available on the Company's website approximately two hours after the event.
About XPOVIO® (selinexor)
XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the
For more information about Karyopharm's products or clinical trials, please contact the Medical Information department at: Tel: +1 (888) 209-9326; Email: medicalinformation@karyopharm.com
XPOVIO® (selinexor) is a prescription medicine approved:
- In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (XVd).
- In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody (Xd).
- For the treatment of adult patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
SELECT IMPORTANT SAFETY INFORMATION
Warnings and Precautions
- Thrombocytopenia: Monitor platelet counts throughout treatment. Manage with dose interruption and/or reduction and supportive care.
- Neutropenia: Monitor neutrophil counts throughout treatment. Manage with dose interruption and/or reduction and granulocyte colony‐stimulating factors.
- Gastrointestinal Toxicity: Nausea, vomiting, diarrhea, anorexia, and weight loss may occur. Provide antiemetic prophylaxis. Manage with dose interruption and/or reduction, antiemetics, and supportive care.
- Hyponatremia: Monitor serum sodium levels throughout treatment. Correct for concurrent hyperglycemia and high serum paraprotein levels. Manage with dose interruption, reduction, or discontinuation, and supportive care.
- Serious Infection: Monitor for infection and treat promptly.
- Neurological Toxicity: Advise patients to refrain from driving and engaging in hazardous occupations or activities until neurological toxicity resolves. Optimize hydration status and concomitant medications to avoid dizziness or mental status changes.
- Embryo‐Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential and males with a female partner of reproductive potential, of the potential risk to a fetus and use of effective contraception.
- Cataract: Cataracts may develop or progress. Treatment of cataracts usually requires surgical removal of the cataract.
Adverse Reactions
- The most common adverse reactions (≥
20% ) in patients with multiple myeloma who receive XVd are fatigue, nausea, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, decreased weight, cataract and vomiting. Grade 3‐4 laboratory abnormalities (≥10% ) are thrombocytopenia, lymphopenia, hypophosphatemia, anemia, hyponatremia and neutropenia. In theBOSTON trial, fatal adverse reactions occurred in6% of patients within 30 days of last treatment. Serious adverse reactions occurred in52% of patients. Treatment discontinuation rate due to adverse reactions was19% . - The most common adverse reactions (≥
20% ) in patients with multiple myeloma who receive Xd are thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea and upper respiratory tract infection. In the STORM trial, fatal adverse reactions occurred in9% of patients. Serious adverse reactions occurred in58% of patients. Treatment discontinuation rate due to adverse reactions was27% . - The most common adverse reactions (incidence ≥
20% ) in patients with DLBCL, excluding laboratory abnormalities, are fatigue, nausea, diarrhea, appetite decrease, weight decrease, constipation, vomiting, and pyrexia. Grade 3‐4 laboratory abnormalities (≥15% ) are thrombocytopenia, lymphopenia, neutropenia, anemia, and hyponatremia. In the SADAL trial, fatal adverse reactions occurred in3.7% of patients within 30 days, and5% of patients within 60 days of last treatment; the most frequent fatal adverse reactions was infection (4.5% of patients). Serious adverse reactions occurred in46% of patients; the most frequent serious adverse reaction was infection (21% of patients). Discontinuation due to adverse reactions occurred in17% of patients.
Use In Specific Populations
Lactation: Advise not to breastfeed.
For additional product information, including full prescribing information, please visit www.XPOVIO.com.
To report SUSPECTED ADVERSE REACTIONS, contact Karyopharm Therapeutics Inc. at 1‐888‐209‐9326 or FDA at 1‐800‐FDA‐1088 or www.fda.gov/medwatch.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's guidance on its 2025 total revenue, 2025 U.S. net product revenue and 2025 R&D and SG&A expenses; expected cash runway and liquidity; Karyopharm's exploration of strategic alternatives and financing transactions; expectations with respect to commercialization efforts; the ability of selinexor to treat patients with multiple myeloma, endometrial cancer, myelofibrosis, diffuse large B-cell lymphoma and other diseases; and expectations with respect to the clinical development plans and potential regulatory submissions of selinexor. Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond Karyopharm's control, that may cause actual events or results to differ materially from Karyopharm's current expectations. For example, there can be no guarantee that Karyopharm will successfully commercialize XPOVIO or that any of Karyopharm's drug candidates, including selinexor, will successfully complete necessary clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in the development or commercialization of Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the adoption of XPOVIO in the commercial marketplace, the timing and costs involved in commercializing XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval; the ability to obtain and retain regulatory approval of XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval; Karyopharm's results of clinical trials and preclinical trials, including subsequent analysis of existing data and new data received from ongoing and future trials; the content and timing of decisions made by the
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
KARYOPHARM THERAPEUTICS INC. | ||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
(unaudited) | ||||||||||||||||
(in thousands, except per share amounts) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Revenues: | ||||||||||||||||
Product revenue, net | $ | 29,681 | $ | 28,032 | $ | 50,735 | $ | 54,038 | ||||||||
License and other revenue | 8,248 | 14,754 | 17,209 | 21,874 | ||||||||||||
Total revenue | 37,929 | 42,786 | 67,944 | 75,912 | ||||||||||||
Operating expenses: | ||||||||||||||||
Cost of sales | 1,051 | 1,465 | 2,352 | 3,376 | ||||||||||||
Research and development | 32,788 | 38,371 | 67,406 | 73,796 | ||||||||||||
Selling, general and administrative | 28,477 | 31,070 | 55,829 | 60,619 | ||||||||||||
Total operating expenses | 62,316 | 70,906 | 125,587 | 137,791 | ||||||||||||
Loss from operations | (24,387) | (28,120) | (57,643) | (61,879) | ||||||||||||
Other income (expense): | ||||||||||||||||
Interest income | 613 | 1,930 | 1,613 | 4,086 | ||||||||||||
Interest expense | (11,228) | (8,949) | (22,222) | (14,833) | ||||||||||||
Gain on extinguishment of debt | — | 44,702 | — | 44,702 | ||||||||||||
Other (expense) income, net | (2,210) | 14,296 | 17,614 | 14,492 | ||||||||||||
Total other income (expense), net | (12,825) | 51,979 | (2,995) | 48,447 | ||||||||||||
(Loss) income before income taxes | (37,212) | 23,859 | (60,638) | (13,432) | ||||||||||||
Income tax provision | (40) | (67) | (76) | (138) | ||||||||||||
Net (loss) income | $ | (37,252) | $ | 23,792 | $ | (60,714) | $ | (13,570) | ||||||||
Basic net (loss) income per share | $ | (4.32) | $ | 2.26 | $ | (7.11) | $ | (1.72) | ||||||||
Diluted net loss per share | $ | (4.32) | $ | (2.97) | $ | (7.11) | $ | (7.16) | ||||||||
Weighted-average number of common shares | 8,620 | 8,069 | 8,545 | 7,884 | ||||||||||||
Weighted-average number of common shares | 8,620 | 10,295 | 8,545 | 8,472 | ||||||||||||
All share amounts and per share amounts in this press release have been adjusted to reflect a 1-for-15 reverse split of our common stock, which we effected on February 25, 2025. |
KARYOPHARM THERAPEUTICS INC. | |||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
(unaudited) | |||||||
(in thousands) | |||||||
June 30, | December 31, | ||||||
Assets | |||||||
Cash, cash equivalents and investments | $ | 51,697 | $ | 108,712 | |||
Restricted cash | 350 | 338 | |||||
Accounts receivable | 32,932 | 30,766 | |||||
Other assets | 19,900 | 24,602 | |||||
Total assets | $ | 104,879 | $ | 164,418 | |||
Liabilities and stockholders' deficit | |||||||
Convertible senior notes due 2025 | $ | 24,484 | $ | 24,426 | |||
Convertible senior notes due 2029 | 62,684 | 68,345 | |||||
Senior secured term loan | 95,816 | 94,603 | |||||
Deferred royalty obligation | 73,499 | 73,499 | |||||
Other liabilities | 87,322 | 89,562 | |||||
Total liabilities | 343,805 | 350,435 | |||||
Total stockholders' deficit | (238,926) | (186,017) | |||||
Total liabilities and stockholders' deficit; 8,647 and 8,413 shares issued and | $ | 104,879 | $ | 164,418 | |||
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-reports-second-quarter-2025-financial-results-and-highlights-recent-company-progress-302525657.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
What were Karyopharm's (KPTI) Q2 2025 financial results?
When will Karyopharm report top-line results for the Phase 3 SENTRY trial?
What is Karyopharm's financial outlook for 2025?
What is KPTI's current cash position and runway?
How is XPOVIO performing in the commercial setting?
